Evidence map›Paper›PMID 25910265›Full record

ArticlePloS one2015

Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors.

Riccardo Zanni, Maria Galvez-Llompart, Cecilia Morell, Nieves Rodríguez-Henche, Inés Díaz-Laviada, Maria Carmen Recio-Iglesias, Ramon Garcia-Domenech, Jorge Galvez

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Computational toxicology (Amsterdam, Netherlands) · 2021
    Article
  5. Molecular Topology for the Search of New Anti-MRSA Compounds.International journal of molecular sciences · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Riccardo ZanniDepartment of Physical Chemistry, School of Pharmacy, University of Valencia, Valencia, Spain; Department of Pharmacology, School of Pharmacy, University of Valencia, Valencia, Spain.
Maria Galvez-LlompartDepartment of Physical Chemistry, School of Pharmacy, University of Valencia, Valencia, Spain; Department of Pharmacology, School of Pharmacy, University of Valencia, Valencia, Spain.
Cecilia MorellDepartment of System Biology, Biochemistry and Molecular Biology Unit, School of Medicine, University of Alcala, Alcalá de Henares, Spain.
Nieves Rodríguez-HencheDepartment of System Biology, Biochemistry and Molecular Biology Unit, School of Medicine, University of Alcala, Alcalá de Henares, Spain.
Inés Díaz-LaviadaDepartment of System Biology, Biochemistry and Molecular Biology Unit, School of Medicine, University of Alcala, Alcalá de Henares, Spain.
Maria Carmen Recio-IglesiasDepartment of Pharmacology, School of Pharmacy, University of Valencia, Valencia, Spain.
Ramon Garcia-DomenechDepartment of Physical Chemistry, School of Pharmacy, University of Valencia, Valencia, Spain.
Jorge GalvezDepartment of Physical Chemistry, School of Pharmacy, University of Valencia, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeColorectal and prostate cancers are two of the most common types and cause of a high rate of deaths worldwide. Therefore, any strategy to stop or at least slacken the development and progression of malignant cells is an important therapeutic choice. The aim of the present work is the identification of novel cancer chemotherapy agents. Nowadays, many different drug discovery approaches are available, but this paper focuses on Molecular Topology, which has already demonstrated its extraordinary efficacy in this field, particularly in the identification of new hit and lead compounds against cancer. This methodology uses the graph theoretical formalism to numerically characterize molecular structures through the so called topological indices. Once obtained a specific framework, it allows the construction of complex mathematical models that can be used to predict physical, chemical or biological properties of compounds. In addition, Molecular Topology is highly efficient in selecting and designing new hit and lead drugs. According to the aforementioned, Molecular Topology has been applied here for the construction of specific Akt/mTOR and β-catenin inhibition mathematical models in order to identify and select novel antitumor agents. EXPERIMENTAL APPROACH: Based on the results obtained by the selected mathematical models, six novel potential inhibitors of the Akt/mTOR and β-catenin pathways were identified. These compounds were then tested in vitro to confirm their biological activity. CONCLUSION AND IMPLICATIONS: Five of the selected compounds, CAS n° 256378-54-8 (Inhibitor n°1), 663203-38-1 (Inhibitor n°2), 247079-73-8 (Inhibitor n°3), 689769-86-6 (Inhibitor n°4) and 431925-096 (Inhibitor n°6) gave positive responses and resulted to be active for Akt/mTOR and/or β-catenin inhibition. This study confirms once again the Molecular Topology's reliability and efficacy to find out novel drugs in the field of cancer.

Indexed as

Quantitative Structure-Activity RelationshipAntineoplastic Agentsbeta CateninBiological ProductsCell Line, TumorCell SurvivalDrug DiscoveryHumansMolecular StructureNeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAntineoplastic Agentsbeta CateninBiological ProductsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID25910265
PMCPMC4409212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.